Cowen Remains Bullish on Gilead Sciences (GILD) Following Data Release

Cowen reiterated an Outperform rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD) following the release top-line data from the Ph. III ASTRAL trials of SOF+VEL.

Analyst Phil Nadeau commented, "GILD released top-line data from the Ph. III ASTRAL trials of SOF+VEL. Twelve weeks of the fixed-dosed combination generated >94% SVR12 rates in GT1-6 including decompensated cirrhotics (when combined with RBV). These data suggest that SOF+VEL is a viable pan-genotypic HCV regimen, and that GILD now has a potent regimen for GT 3 patients. We remain at Outperform."

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $108.44 yesterday.

You May Also Be Interested In

• HSBC Upgrades Gilead Sciences (GILD) to Hold
• GATX Corp. (GATX) PT Raised to $137 at TD Cowen
• Halliburton (HAL) PT Raised to $48 at TD Cowen